Summary: Spinal cord injuries often cause lasting paralysis because damaged nerve fibers have a limited ability to regrow. A new study presents an alternative strategy: rather than trying to regenerate severed axons, researchers used a designer protein called hyper-interleukin-6 (hIL-6) to rewire intact neural circuits. By turning the motor cortex into a local source of this signaling protein, the team induced collateral sprouting from spared fibers and successfully restored coordinated walking in paralyzed mice.
Delivered via a viral vector to the motor cortex, hIL-6 travels along existing axons to downstream motor regions and triggers plastic changes in descending pathways, particularly serotonergic neurons in the brainstem. The result is rerouting of motor commands around the lesion through newly formed collateral branches, producing significant improvements in locomotion without shrinking the lesion or replacing lost cells.
Key Facts
- The hIL-6 messenger: Hyper-interleukin-6 is a potent designer cytokine that can directly engage neuronal signaling. In this study it was encoded by an AAV2 viral vector injected into the motor cortex, causing cortical neurons to produce the protein themselves.
- Transneuronal transport: Once synthesized in cortical neurons, hIL-6 is carried along intact axons to subcortical motor centers, including the brainstem, where it activates downstream neurons involved in locomotor control.
- Plasticity rather than regeneration: The therapy does not reduce lesion size or replace cells lost to injury. Instead, it promotes circuit plasticity: spared axons sprout collateral branches that form functional connections bypassing the damaged area.
- Restored gait and coordination: Across models of mild, moderate, and severe contusion, treated animals showed clear improvements in walking ability and, importantly, recovered coordinated gait patterns that were absent in control groups.
- Serotonergic pathways are essential: The authors showed that selectively removing serotonergic neurons in the brainstem eliminated the functional gains, demonstrating that these descending circuits are primary mediators of recovery after hIL-6 treatment.
Source: University of Cologne
Context and rationale: Most spinal cord injuries are contusions in which some axons are compressed or damaged while others remain intact. Current treatments offer limited improvements in recovery. The research led by Professor Dietmar Fischer at the Institute of Pharmacology II, University Hospital Cologne, explores a different angle: using the nervous system’s remaining connections as a scaffold for functional recovery by stimulating them from the motor cortex downwards.
In the study, intracortical injection of an AAV2 vector encoding hIL-6 turned cortical neurons into a sustained source of the cytokine. That protein then moved transneuronally to activate subcortical neurons, including raphe nuclei in the medulla that give rise to descending serotonergic fibers. These fibers play an important role in generating the rhythmic motor patterns needed for walking.
Rather than promoting long-distance regeneration of corticospinal tract axons across the lesion, the treatment mainly increased the number and length of descending serotonergic axons in the lumbar spinal cord and reduced retraction of corticospinal axons. The authors report that these changes were sufficient to restore coordinated, weight-bearing stepping in animals with a range of contusion severities.
Professor Fischer emphasizes that the observed improvements arise from remodeling of intact circuits: “The treatment did not reduce lesion size or prevent neuronal loss. Instead, it triggered new collateral sprouting and a reorganization of remaining pathways that bypass the injured area.”
The investigators also validated the causal role of serotonergic neurons by selectively ablating them; doing so abolished the locomotor improvements, confirming these descending fibers are critical for the functional benefits produced by hIL-6.
Limitations and next steps: While results in mice are encouraging, translation to humans will require careful additional studies. Key questions remain about long-term safety of the viral delivery method, optimal dosing for the larger human brain and spinal cord, potential off-target effects, and the durability of functional improvements. The researchers stress that further preclinical work is needed before clinical trials could be considered.
Key Questions Answered:
A: Rather than reconstructing a severed pathway, hIL-6 stimulates spared axons to sprout collateral branches that create alternative routes around the lesion. These new side branches carry motor signals past the injury and re-establish functional connections required for coordinated stepping.
A: Injecting the vector into the motor cortex turns the movement control region into a distribution hub. Cortical neurons synthesize hIL-6 and transport it along their axons to deeper motor centers, ensuring the cytokine reaches the circuits that control walking.
A: Human application is not imminent. The promising preclinical data must be followed by rigorous safety testing, dose-finding studies, and thorough evaluation of long-term effects of the viral vector and cytokine expression before clinical trials are possible.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this spinal cord injury and genetics research news
Author: Eva Schissler
Source: University of Cologne
Contact: Eva Schissler – University of Cologne
Image: The image is credited to Neuroscience News
Original Research: Open access. “Transneuronal cytokine delivery promotes functional recovery across spinal cord contusion severities via descending circuit plasticity” by Marco Leibinger, Igor Moskaliov, Chinonso-John Ani, Dalia Halawani, and Dietmar Fischer. Neurobiology of Disease. DOI: 10.1016/j.nbd.2026.107399
Abstract
Transneuronal cytokine delivery promotes functional recovery across spinal cord contusion severities via descending circuit plasticity
Spinal cord injury often causes persistent motor and sensory deficits. Complete injuries can abolish function below the lesion, while incomplete contusions leave partial connectivity intact. Intracortical delivery of an AAV2 vector encoding hyper-interleukin-6 (AAV2-hIL-6) enhances recovery after spinal cord injury by transneuronally stimulating raphe nuclei. This study confirms that AAV2-hIL-6 activates subcortical neurons in the medulla and demonstrates efficacy in mouse models of mild, moderate, and severe contusion injury. Across all severities, AAV2-hIL-6 produced significant improvements in locomotor function relative to AAV2-GFP controls. Lesion size and neuronal loss correlated with contusion severity and were not changed by AAV2-hIL-6 treatment, yet the therapy robustly increased the number and length of descending serotonergic axons in the lumbar cord. Selective ablation of serotonergic neurons abolished functional gains, confirming their essential role. Although AAV2-hIL-6 reduced corticospinal tract axon retraction, it did not induce axon growth beyond the lesion, indicating that corticospinal regeneration was not required for recovery. Intracortical AAV2-hIL-6 delivery therefore drives circuit remodeling and functional restoration across contusion severities and highlights its potential as a therapeutic approach for spinal cord injury with spared pathways.